July 2019
Policy brief
HIV Treatment
Nature Reviews Microbiology Vol. 17 (2019)pp.51-62
Antimicrobial susceptibility testing (AST) technologies help to accelerate the
initiation of targeted antimicrobial therapy for patients with infections and could potentially
extend the lifespan of current narrow- spectrum antimicrobials. Althoug...h conceptually new and
rapid AST technologies have been described, including new phenotyping methods, digital
imaging and genomic approaches, there is no single major, or broadly accepted, technological
breakthrough that leads the field of rapid AST platform development
more
Emergencias 2021: 33: 42-58
PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-
aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and
elimination program...s. There is now a priority to ensure that the drug reaches all at-risk PSAC
in endemic areas, including hard-to-reach areas and populations. This study aimed to deter-
mine schistosomiasis treatment-related contextual factors among fishermen and island popu-
lations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ.
more
Accelerating HIV prevention to reduce new infections by 75%
Technical brief by the H4+ (UNAIDS, UNFPA, UNICEF, UN Women, WHO and the World Bank)
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
Networking for Policy Change: TB/HIV Participant’s Guide
WHO/HTM/TB/2007.384b
“TB is too often a death sentence for people with AIDS. It does not have to be this
way.”
-Nelson Mandela, International conference on HIV and AIDS, Bangkok, Thailand, July 2004.
First WHO Global Ministerial Conference
Ending TB in the Sustainable Development Era: A Multisectoral Response
Moscow, Russian Federation, 16-17 November 2017
The study analyses the current situation of children with disabilities in relation to realizing their rights and accessing basic services, as well as their life experiences in their communities. It also focuses on identifying the barriers created by society that prevent children with disabilities fr...om enjoying their human rights. This includes identifying negative attitudes; environmental and communication barriers; gaps in policies or their effective implementation.
The report reveals that children with disabilities in Myanmar are less likely to access services in health or education; rarely have their voices heard in society; and face daily discrimination as objects of pity. It also highlights how inadequate policies and legislation contribute to the challenges these children face.
The information available in this publication should be useful for policy makers, development partners and Disabled Persons Organisations to promote the realization of the rights of all children with disabilities.
more
This external performance evaluation of the Malawi Girls’ Empowerment through Education and Health Activity (ASPIRE), conducted 2.5 years after ASPIRE began, establishes the activity’s progress against its objectives, proposes adaptations for the final year, and captures lessons for application ...in future girls’ empowerment, health, and education programming in Malawi.
more
Areas for action include: increasing prioritisation and awareness of dementia; reducing the risk of dementia; diagnosis, treatment and care; support for dementia carers; strengthening information systems for dementia; and research and innovation.